Lucentis and Vascular rupture - a phase IV clinical study of FDA data

Summary:

Vascular rupture is reported as a side effect among people who take Lucentis (ranibizumab), especially for people who are female, 60+ old, also take Avastin, and have Age-related macular degeneration.

The phase IV clinical study analyzes which people have Vascular rupture when taking Lucentis. It is created by eHealthMe based on reports of 25,577 people who have side effects when taking Lucentis from the FDA, and is updated regularly.

What is Lucentis?

Lucentis has active ingredients of ranibizumab. It is often used in macular degeneration. eHealthMe is studying from 25,647 Lucentis users. Check the latest studies of Lucentis.

What is Vascular rupture?

Vascular rupture is found to be associated with 248 drugs and 293 conditions by eHealthMe. Check the latest studies of Vascular rupture.



On Jul, 06, 2026

25,577 people reported to have side effects when taking Lucentis.
Among them, 14 people (0.05%) have Vascular rupture.

Could Lucentis cause Vascular rupture?

Among these 14 people:

What is the gender of people who have Vascular rupture when taking Lucentis? *

  • female: 57.14 %
  • male: 42.86 %

What is the age of people who have Vascular rupture when taking Lucentis? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

What are other drugs people take besides Lucentis? *

  1. Avastin: 2 people, 14.29%
  2. Metformin: 1 person, 7.14%

What are other side effects people have besides Vascular rupture? *

  1. Visual Impairment: 3 people, 21.43%
  2. Visual Acuity Reduced (reduced clearness of vision): 3 people, 21.43%
  3. Eye Haemorrhage (bleeding in the eye): 3 people, 21.43%
  4. Injection Site Pain: 1 person, 7.14%
  5. Blindness Unilateral: 1 person, 7.14%
  6. Cataract (clouding of the lens inside the eye): 1 person, 7.14%
  7. Diabetes: 1 person, 7.14%
  8. Drug Ineffective: 1 person, 7.14%
  9. Eye Disorder: 1 person, 7.14%
  10. Haemorrhage (bleeding): 1 person, 7.14%

What are the existing conditions these people have? *

  1. Age-Related Macular Degeneration: 4 people, 28.57%
  2. Glaucoma (increased fluid pressure in the eye with vision loss): 3 people, 21.43%
  3. Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 1 person, 7.14%
  4. Peripheral Swelling: 1 person, 7.14%
  5. Maculopathy (a condition or disease of the macula, the small spot in the retina where vision is keenest): 1 person, 7.14%
  6. Gout (uric acid crystals building up in the body): 1 person, 7.14%
  7. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 7.14%
  8. Diabetic Retinopathy (damage to the retina caused by complications of diabetes): 1 person, 7.14%
  9. Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 1 person, 7.14%
  10. Diabetic Eye Disease: 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Lucentis and have Vascular rupture?

- Check whether Vascular rupture is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lucentis:

Vascular rupture treatments and more:

How severe was Vascular rupture and when was it recovered:

Expand to all the drugs that have ingredients of ranibizumab:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lucentis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Vascular rupture:

Browse all the conditions that are associated with Vascular rupture:


How the study uses the data?

The study uses data from the FDA. It is based on ranibizumab (the active ingredients of Lucentis) and Lucentis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: